SCHEMBL718576

SCHEMBL718576

COCc1c(C(=O)OC)oc2ccc(F)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.53
NPC1 O15118 4/20 0.53
KMT2A Q03164 2/20 0.53
RXFP1 Q9HBX9 2/20 0.53
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 2/20 0.45
HTT P42858 2/20 0.45
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 4/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722465 0.89 RAB9A (0.46) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL719098 0.86 PLK1 (0.50) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL25338376 0.80 KDM4E (0.49) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL724096 0.80 MAPT (0.64) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL719900 0.79 KMT2A (0.50) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL18496523 0.79 KDM4E (0.70) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL29224907 0.76 PLK1 (0.53) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL31231850 0.75 RAB9A (0.43) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL25340462 0.75 RAB9A (0.43) RAB9ANPC1KMT2ARXFP1KDM4E
SCHEMBL717463 0.75 KMT2A (0.44) RAB9ANPC1KMT2ARXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885KMT2A 1298/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.